# Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

> **NCT02558400** · PHASE3 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 718 (actual)

## Conditions studied

- Open-angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** PG324 Ophthalmic Solution 0.02%/0.005%
- **DRUG:** Netarsudil (AR-13324) Ophthalmic Solution 0.02%
- **DRUG:** Latanoprost Ophthalmic Solution 0.005%

## Key facts

- **NCT ID:** NCT02558400
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-18
- **Primary completion:** 2017-05-17
- **Final completion:** 2017-06-30
- **Target enrollment:** 718 (ACTUAL)
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02558400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02558400, "Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02558400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*